Novartis drug helps rare tumors, filing this year (Reuters, 11 October 2010)
11 Oct 2010
Novartis have presented data from a phase III study of their pancreatic neuroendocrine tumour drug Afinitor (generic name everolimus) at the European Society for Medical Oncology congress in Milan.
